Ascendis Pharma A (ASND) Liabilities and Shareholders Equity (2012 - 2026)

Ascendis Pharma A has disclosed Liabilities and Shareholders Equity across 15 years of filings, most recently posting $2.3 billion for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $2.3 billion, up 110.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.4 billion (down 0.8% YoY), and the FY2025 annual result was $1.5 billion, down 54.89% from the prior year.
• Liabilities and Shareholders Equity came in at $2.3 billion for Q1 2026 at Ascendis Pharma A, up from $1.5 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $3.4 billion in Q4 2024 to a low of $816.6 million in Q2 2024.
• The 5-year median for Liabilities and Shareholders Equity is $1.2 billion (2024), against an average of $1.3 billion.
• Across the five-year window, Liabilities and Shareholders Equity jumped 278.36% in 2024 and plunged 54.89% in 2025, its largest moves.
• Ascendis Pharma A's Liabilities and Shareholders Equity stood at $1.1 billion in 2022, then retreated by 20.1% to $888.3 million in 2023, then surged by 278.36% to $3.4 billion in 2024, then slumped by 54.89% to $1.5 billion in 2025, then surged by 54.68% to $2.3 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $2.3 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.